Unraveling the Prognostic Impact of Co-Occurring High-Risk Cytogenetic Abnormalities in Multiple Myeloma

Highlight

• Co-occurrence of two or more high-risk cytogenetic abnormalities (HRCAs) significantly worsens progression-free and overall survival in multiple myeloma (MM).
• This adverse prognostic impact is consistent across newly diagnosed (NDMM) and relapsed/refractory (RRMM) settings as well as a variety of treatment modalities.
• A federated meta-analysis of 24 randomized controlled trials with 13,926 MM patients confirms these findings using a standardized cytogenetic algorithm.
• Recognition of ‘‘double-hit’’ cytogenetic profiles enables more precise risk stratification and informs the development of novel therapeutic approaches.

Study Background and Disease Burden